pharmaphorum August 15, 2022
Phil Taylor

In draft guidance, NICE has said that AliveCor’s ECG recording device should be an option to check or heart disturbances in patients who take antipsychotic medicines. 

The KardiaMobile 6L – first introduced in 2019 – is an update to AliveCor’s earlier ECG with an additional electrode to make it a six-lead device that improves the accuracy of heart rhythm measurements.

Like its predecessor, it links to a smartphone app which includes an artificial intelligence system that can detect for example whether atrial fibrillation, bradycardia (slow heart rhythm), tachycardia (fast heart rhythm) or a normal rhythm is detected.

The draft guidance (PDF) cover use of the device and app for people taking antipsychotics, who need to be tested before and during...

Today's Sponsors

pCare
Institute for Healthcare Improvement
Crossover Health

Today's Sponsors

ZeOmega
Holon

Today's Sponsor

Premier

 
Topics: Digital Health, Medical Devices, Patient / Consumer, Provider, Technology
The medtech industry’s new paradigm: Real world evidence collection [Sponsored]
European AI Act could have ‘significant impact’ on manufacturers, medtech group warns
Optellum, AI Lung Cancer Diagnosis Innovator, Secures $14M Series A Funding to Accelerate Expansion
Your clinical decision support software may now be regulated by FDA as a medical device
FDA drops push for medical device cybersecurity requirement